INSUBCONTINENT EXCLUSIVE:
Cadila Healthcare is primarily engaged in the manufacture of generic drugs.Cadila Healthcare Limited, reported a growth of 73 per cent in
net profit on a consolidated basis to Rs 679 crore in the January-March quarter of the financial year 2020-21
According to a regulatory filing by the multinational pharmaceutical company to the stock exchanges on Thursday, May 27, Cadila Healthcare
reported a net profit of Rs 391 crore in the corresponding quarter of the previous fiscal
with revenues at Rs 1,772 crore
Healthcare settled 0.19 per cent lower at Rs 626.70 on the BSE
On Thursday, Cadila Healthcare opened on the BSE at Rs 637, inching to an intra day high of Rs 638 and an intra day low of Rs 621.55,
throughout the trading session.
